⚖️ FTC Monitoring Pharma Patent Cliff & Market Competition
The U.S. Federal Trade Commission is keeping a close watch on how pharmaceutical companies respond as major drugs approach patent expiration—aiming to prevent anticompetitive practices and ensure fair pricing and access.
At the Reuters Events Pharma USA Conference, Dan Guarnera highlighted the agency’s focus on enabling smooth entry for generics under patent laws.
💊 Drugs nearing exclusivity loss include: • Keytruda • Eliquis • Darzalex
📉 Why it matters: The “patent cliff” could reshape the pharma landscape—bringing lower prices but also raising concerns about delayed competition.
🔍 The FTC is also reviewing healthcare mergers, including the halted deal between Alcon and LENSAR over competition concerns.
💡 Takeaway: Patent expirations are a key moment for balancing affordability, innovation, and market fairness.
📌 Contact IP Consulting Group For a Free tailored IP insights and legal guidance: 📧 [email protected] 🌐 www.ipconsultinggroups.com 📞 DC: +1 (202) 666-8377 | MD: +1 (240) 477-6361